Nils Florian Trautwein, Clemens Hinterleitner, Lena Sophie Kiefer, Stephan Singer, Sven Mattern, Johannes Schwenck, Gerald Reischl, Bence Sipos, Ulrich M Lauer, Helmut Dittmann, Lars Zender, Christian la Fougère, Martina Hinterleitner
AIM/INTRODUCTION: Peptide receptor radionuclide therapy (PRRT) represents a cornerstone of treatment regimens for patients with low proliferative neuroendocrine tumors (NETs). However, in patients experiencing somatostatin receptor-positive NET with higher proliferation rates, a value and potential therapeutic benefit of PRRT as part of multimodal treatment approaches and potentially with addition of radiosensitizing agents has not yet been established. PATIENTS AND METHODS: In this study, 20 patients with histologically confirmed gastroenteropancreatic (GEP) NET with proliferation rates (Ki67) between 15% and 55% were treated either with PRRT only (n = 10) or with a combination therapy (n = 10) comprising PRRT and capecitabine/temozolomide (CAP/TEM) for at least 2 consecutive cycles...
January 23, 2024: Clinical Nuclear Medicine